Hengrui Approved to Launch Antifungal for Vulvovaginal Candidiasis
publication date: Aug 22, 2023
Jiangsu Hengrui Pharma was approved to launch an azole antifungal to treat severe vulvovaginal candidiasis, commonly known as yeast infections. A novel oral therapy, Oteseconazole Capsules are designed to have greater selectivity, fewer side effects and improved potency than current treatments. The therapy may also be effective for other systemic fungal infections. In 2019, Hengrui in-licensed greater China rights for Oteseconazole Capsules from Mycovia Pharma of North Carolina. It signed a standard pact with Mycovia for the rights, including upfront, milestone and royalty payments, though specific details of the agreement were not disclosed. More details....
Stock Symbol: (SHA: 600276)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.